We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Acorda Recognized by National Organization for Rare Disorders for Contribution to Treatment of MS
News

Acorda Recognized by National Organization for Rare Disorders for Contribution to Treatment of MS

Acorda Recognized by National Organization for Rare Disorders for Contribution to Treatment of MS
News

Acorda Recognized by National Organization for Rare Disorders for Contribution to Treatment of MS

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Acorda Recognized by National Organization for Rare Disorders for Contribution to Treatment of MS"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Acorda Therapeutics, Inc. has announced the National Organization for Rare Disorders (NORD) is recognizing the Company for its efforts to develop therapies for rare diseases.

Earlier this year, Acorda received approval from the U.S. Food and Drug Administration (FDA) for AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, the first therapy to improve walking in people with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. The award was presented at the 2010 NORD Partners in Progress Gala in Washington, D.C.

“NORD plays a critical role in advocating for public policies that encourage public and private investment in development of therapies for rare diseases. This effort helps to ensure that patients with rare diseases have hope for future treatments.”

“NORD plays a critical role in advocating for public policies that encourage public and private investment in development of therapies for rare diseases. This effort helps to ensure that patients with rare diseases have hope for future treatments,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. ”NORD is also an invaluable resource for people affected by rare diseases, providing information, education and support services to patients, families, medical professionals, and the public. We are honored to be recognized by an organization that has made such important contributions to medicine and society.”

“Multiple sclerosis is a progressive disease with devastating health consequences, and new treatment options are needed to improve the lives of people with MS,” said Peter L. Saltonstall, President and CEO of NORD. “We commend Acorda for its commitment to bringing novel therapies to market for people with MS and other neurological diseases.”

In the United States, a disease is considered rare if it affects fewer than 200,000 Americans. According to the National Institutes of Health (NIH), there are nearly 7,000 such diseases. Although MS is now estimated to affect between 400,000-500,000 Americans, it was classified as a rare disease at the time that Acorda began developing AMPRYA.
Advertisement